The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1130
May 13, 2002
View Complete Issue         Table of Contents 2019 
Issue 1130
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Fondaparinux (Arixtra), A New Anticoagulant
May 13, 2002 (Issue: 1130)
Fondaparinux (Arixtra - Organon Sanofi-Synthelabo), a synthetic analog of heparin, has been approved by the FDA for prevention of deep vein thrombosis (DVT) after hip fracture surgery or knee or hip replacement.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1130
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.